Bloom Burton Predicts BioSyent’s FY2026 Earnings (CVE:RX)

BioSyent Inc. (CVE:RX) – Investment analysts at Bloom Burton upped their FY2026 EPS estimates for BioSyent in a note issued to investors on Monday, August 25th. Bloom Burton analyst D. Martin now expects that the company will earn $0.87 per share for the year, up from their prior forecast of $0.86. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2027 earnings at $0.95 EPS.

BioSyent Price Performance

RX stock opened at C$12.10 on Thursday. The company has a market cap of C$138.39 million, a price-to-earnings ratio of 19.64 and a beta of 0.93. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. BioSyent has a 12 month low of C$9.20 and a 12 month high of C$12.40. The firm has a 50-day moving average of C$11.61 and a two-hundred day moving average of C$11.27.

BioSyent Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 29th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 1.7%. BioSyent’s dividend payout ratio is presently 29.21%.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.